Yaz vs Yasmin: Same Progestin, Different Estrogen Dose and a Different Pill Schedule

Yaz and Yasmin are made by the same company, contain the same progestin at the same dose, and are constantly confused for each other. They are not interchangeable. Two things separate them: the amount of ethinyl estradiol, and how many active tablets are in the pack. Those two differences produce different bleeding patterns, different licensed uses in the United States, and a meaningfully different experience for some women. This guide sets out exactly what changes and what does not.

The composition side by side

Both products contain drospirenone 3 mg. That figure is identical and it does not vary between them. The estrogen differs: Yaz contains ethinyl estradiol 0.02 mg, and Yasmin contains ethinyl estradiol 0.03 mg. That is a fifty percent higher estrogen dose in Yasmin.

The pack layout differs too. Yaz is a 24 plus 4 product: twenty-four active tablets followed by four inert tablets. Yasmin follows the older 21 plus 7 pattern: twenty-one active tablets followed by seven inert. Same 28-day pack, different split.

Why the 24 plus 4 schedule exists

Shortening the hormone-free interval from seven days to four was a deliberate design change, not a packaging quirk. During the hormone-free days, follicular activity in the ovary starts to resume. A shorter break gives less opportunity for that to happen, which narrows the window in which a missed or delayed tablet at the start of the next pack causes a problem.

The practical consequences are a shorter and often lighter withdrawal bleed, and fewer days of the hormone withdrawal symptoms some women get in the pill-free week: headaches, mood dip, pelvic cramping. For women whose main complaint is what happens during the break rather than during the active tablets, the 24 plus 4 layout is the more relevant difference between these two products, more so than the estrogen number.

The licensed indications are not the same

This is the difference most comparisons miss. In United States labelling, Yaz carries three indications: prevention of pregnancy, treatment of premenstrual dysphoric disorder in women who are choosing an oral contraceptive for contraception anyway, and treatment of moderate acne vulgaris in women at least 14 years old who have reached menarche and who want an oral contraceptive for birth control.

Yasmin is licensed for contraception. It does not carry the premenstrual dysphoric disorder indication. The label for Yaz is also explicit that its effectiveness for that condition beyond three menstrual cycles has not been evaluated, and that it has not been studied for premenstrual syndrome as distinct from premenstrual dysphoric disorder. Those are meaningful limits on a claim that gets stretched in marketing.

What premenstrual dysphoric disorder means here

The label defines the condition using the diagnostic criteria in force when it was written: markedly depressed mood, anxiety or tension, mood lability, and persistent anger or irritability, alongside reduced interest in usual activities, concentration difficulty, low energy, appetite or sleep change, and a feeling of being out of control. Physical features include breast tenderness, headache, joint and muscle pain, bloating and weight gain.

Two features define it and both are frequently ignored. Symptoms must occur regularly in the luteal phase and resolve within a few days of menstruation starting. And they must interfere markedly with work, school or relationships. A Cochrane review of drospirenone-containing combined oral contraceptives for premenstrual syndrome (PMID 37365881) found five randomised controlled trials in this area, which is a modest evidence base for a widely made claim.

The drospirenone difference that applies to both

Drospirenone is derived from spironolactone. It has antimineralocorticoid activity, meaning it acts on the same pathway as a potassium-sparing diuretic, and antiandrogenic activity, which is the reason it appears in acne treatment.

The antimineralocorticoid property is why Yaz labelling lists renal impairment and adrenal insufficiency as outright contraindications, which is unusual among combined oral contraceptives. Both conditions impair potassium handling, and adding a potassium-sparing agent on top raises the risk of hyperkalaemia. This applies equally to Yaz, Yasmin and every drospirenone generic.

Adverse reaction rates from the trials

Yaz labelling reports pooled data from contraception trials in 1,056 women and moderate acne trials in 536 women. The reactions occurring in at least two percent were headache or migraine at 6.7 percent, menstrual irregularities at 4.7 percent, nausea or vomiting at 4.2 percent, breast pain or tenderness at 4.0 percent, and mood changes at 2.2 percent.

The premenstrual dysphoric disorder trials produced markedly higher figures for the same product: menstrual irregularities 24.9 percent, nausea 15.8 percent, headache 13.0 percent, breast tenderness 10.5 percent, fatigue 4.2 percent, irritability 2.8 percent, decreased libido 2.8 percent, increased weight 2.5 percent and mood lability 2.1 percent. The drug is identical. The population and the way symptoms were recorded are not. That gap is a good reminder that a single quoted side effect percentage means little without the trial context attached.

Which one for acne

Yaz has the acne indication and Yasmin does not, so on labelling alone Yaz is the answer. The mechanism is the antiandrogenic effect of drospirenone plus the rise in sex hormone binding globulin that oral estrogen produces, which lowers free testosterone.

Worth knowing before choosing on this basis: the label states Yaz should be used for acne only if the patient wants an oral contraceptive for birth control in the first place. It is not intended as an acne drug for someone who does not need contraception. For that situation, a topical retinoid is the more appropriate starting point, and our acne treatment hub covers those options.

Which one for lighter periods and fewer break symptoms

Yaz, on the pack layout rather than the hormone dose. Four hormone-free days instead of seven means a shorter withdrawal bleed and fewer days exposed to hormone withdrawal. Women whose worst symptoms cluster in the pill-free week generally do better on the 24 plus 4 schedule.

Which one for breakthrough bleeding

Yasmin, usually. Unscheduled spotting between periods is one of the commonest reasons a lower estrogen pill is abandoned in the first three months, and moving from 0.02 mg to 0.03 mg of ethinyl estradiol provides more endometrial support. This is the main clinical reason to prefer the higher dose product.

The timing matters. Breakthrough bleeding in the first three cycles usually settles without any change. Persisting past three months, or starting after months of stable cycles, is worth investigating rather than automatically treating with a dose increase.

The generics we stock and how they map

Both formulations are available as Indian generics at a fraction of the branded price. Dronis 20 from Sun Pharma matches the Yaz composition with drospirenone 3 mg and ethinyl estradiol 0.02 mg. Dronis 30 matches Yasmin with drospirenone 3 mg and ethinyl estradiol 0.03 mg. Cipla produces Crisanta and the lower estrogen Crisanta LS in the same drospirenone and ethinylestradiol combination.

The number in a brand name is a useful shortcut across this whole category: it almost always refers to the ethinyl estradiol dose in micrograms, not the progestin. Dronis 20 means 20 micrograms of estrogen. Dronis 30 means 30. The drospirenone is 3 mg in both.

Starting either product

Yaz labelling gives two starting options. A Day 1 start means taking the first active tablet on the first day of menstrual bleeding. A Sunday start means beginning on the first Sunday after bleeding begins. Tablets are taken one daily at the same time, in the order printed on the blister.

The rule that matters most: if the first tablet is taken later than day one of the cycle, the product should not be considered contraceptively effective until seven consecutive days have been taken, and a non-hormonal backup method should be used through those seven days. Our missed pill guide covers what to do when a tablet is forgotten mid-pack.

Switching between them

Moving from Yasmin to Yaz or the other way round is common when bleeding pattern or break-week symptoms are the problem. Finish the current pack of active tablets and start the new product without a gap where a clinician advises it, since that avoids reopening the hormone-free interval.

Give any switch three full cycles before deciding. Bleeding pattern changes are near universal in the first months on a new formulation and most settle. Judging at week three tends to produce an unnecessary second switch.

What is identical between them

The boxed warning is the same on both: cigarette smoking increases the risk of serious cardiovascular events from combined oral contraceptive use, the risk climbs with age and cigarette count, and combined products are contraindicated in women over 35 who smoke. The contraindication list is the same, including deep vein thrombosis or pulmonary embolism now or previously, cerebrovascular or coronary artery disease, inherited or acquired clotting disorders, uncontrolled hypertension, diabetes with vascular disease, migraine with focal neurological symptoms, current or previous breast cancer, liver tumours or liver disease, and undiagnosed abnormal uterine bleeding.

Contraceptive effectiveness is the same. Both suppress ovulation as their primary mechanism. Neither protects against sexually transmitted infection. Our guide to clot risk by progestin generation covers the shared cardiovascular picture in detail.

Choosing between them in one paragraph

Pick Yaz if you want the shorter hormone-free interval, if premenstrual dysphoric disorder is the reason for treating, if moderate acne is a secondary target, or if you want the lower estrogen exposure. Pick Yasmin if breakthrough bleeding on a 20 microgram product has been a problem, or if you are already stable on a 30 microgram formulation and switching solves nothing. If neither applies, the generics cost substantially less for the same composition.

What the two actually cost

Branded Yaz and Yasmin from Bayer Zydus are priced identically in our catalogue at 27.00 US dollars, so on the branded tier the estrogen dose and pack schedule are the only variables. Cost only enters the decision when the generics come into view.

Dronis 20 is 15.00 dollars against 27.00 for Yaz on the same drospirenone 3 mg with ethinylestradiol 0.02 mg composition. Dronis 30 is 19.50 dollars against 27.00 for Yasmin. Cipla prices Crisanta LS at 15.00 and Crisanta at 16.50. Over a year of continuous use the gap between a branded and a generic drospirenone product runs to well over a hundred dollars for a formulation that matches on active ingredient and dose.

What a switch does not fix

Moving between these two products changes estrogen dose and break length. It does not change the progestin, so anything driven by drospirenone specifically carries over unchanged. Potassium-related cautions, the antiandrogenic effect on skin and hair, and the antimineralocorticoid effect on fluid balance are properties of the 3 mg of drospirenone that both products share.

If the problem is mood, libido, headache pattern or breast tenderness and it has persisted past three full cycles on either product, switching between Yaz and Yasmin is unlikely to resolve it. Changing progestin class, or moving to a non-estrogen method, is the change with a mechanism behind it. That is a conversation with a prescriber rather than a substitution at the point of ordering.

Safety information

Yaz and Yasmin are prescription only medicines in the United States, United Kingdom, Australia and Canada. Do not use either if you have renal impairment, adrenal insufficiency, a history of blood clots, a known clotting disorder, uncontrolled high blood pressure, migraine with aura, current or previous breast cancer, or liver disease, or if you are over 35 and smoke. Because drospirenone is potassium sparing, tell your prescriber if you take an ACE inhibitor, an angiotensin receptor blocker, a potassium-sparing diuretic, an aldosterone antagonist, heparin or regular non-steroidal anti-inflammatory drugs. Seek urgent care for one-sided leg pain or swelling, sudden breathlessness, chest pain, sudden severe headache or sudden vision change. Speak to a licensed clinician before starting or switching any contraceptive.

References

• FDA prescribing information for Yaz (drospirenone and ethinyl estradiol tablets): section 1 indications and usage covering contraception, premenstrual dysphoric disorder and moderate acne; section 2 dosage and administration including Day 1 and Sunday start; section 4 contraindications; section 6.1 clinical trials experience adverse reaction rates
• FDA boxed warning common to combined oral contraceptive labelling: cigarette smoking and serious cardiovascular events
• PubMed PMID 37365881, Cochrane review of oral contraceptives containing drospirenone for premenstrual syndrome
• Product composition as supplied: Yaz drospirenone 3 mg with ethinylestradiol 0.02 mg; Yasmin drospirenone 3 mg with ethinylestradiol 0.03 mg; Dronis 20 and Dronis 30 from Sun Pharmaceutical Industries; Crisanta and Crisanta LS from Cipla